Sutro Biopharma Stock Performance
| STRO Stock | USD 0.77 0.03 3.75% |
The entity has a beta of 0.49, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sutro Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sutro Biopharma is expected to be smaller as well. At this point, Sutro Biopharma has a negative expected return of -1.22%. Please make sure to validate Sutro Biopharma's value at risk and rate of daily change , to decide if Sutro Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Acquisition by Venkatesh Srinivasan of 5000 shares of Sutro Biopharma subject to Rule 16b-3 | 01/06/2025 |
2 | Sutro Biopharma and Boehringer Ingelheim BioXcellence collabora | 01/07/2025 |
3 | Brokerages Set Sutro Biopharma, Inc. Target Price at 11.13 - MarketBeat | 01/17/2025 |
4 | Disposition of 25000 shares by Chung Jane of Sutro Biopharma subject to Rule 16b-3 | 02/06/2025 |
5 | Sutro Biopharma stock hits 52-week low at 1.67 amid market challenges - Investing.com | 02/11/2025 |
6 | Man jailed again for breaching city centre ban | 02/28/2025 |
7 | Sutro Biopharma, Inc. Not Doing Enough For Some Investors As Its Shares Slump 25 | 03/04/2025 |
8 | Disposition of 8750 shares by Edward Albini of Sutro Biopharma subject to Rule 16b-3 | 03/05/2025 |
9 | Disposition of 3748 shares by Linda Fitzpatrick of Sutro Biopharma at 1.42 subject to Rule 16b-3 | 03/06/2025 |
10 | Disposition of 6708 shares by Newell William J of Sutro Biopharma at 1.36 subject to Rule 16b-3 | 03/07/2025 |
11 | Sutro Biopharma, Inc. Reports Q4 Loss, Tops Revenue Estimates | 03/13/2025 |
12 | Sutro Biopharma Inc Q4 2024 Earnings Call Highlights Strategic Focus and Financial ... | 03/14/2025 |
13 | Sutro Biopharma lays off dozens of employees in strategic portfolio review - Yahoo News | 03/18/2025 |
| Begin Period Cash Flow | 70.1 M |
Sutro |
Sutro Biopharma Relative Risk vs. Return Landscape
If you would invest 187.00 in Sutro Biopharma on December 22, 2024 and sell it today you would lose (110.00) from holding Sutro Biopharma or give up 58.82% of portfolio value over 90 days. Sutro Biopharma is currently does not generate positive expected returns and assumes 6.6338% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Sutro, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sutro Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sutro Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sutro Biopharma, and traders can use it to determine the average amount a Sutro Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1841
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | STRO |
Estimated Market Risk
| 6.63 actual daily | 59 59% of assets are less volatile |
Expected Return
| -1.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sutro Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sutro Biopharma by adding Sutro Biopharma to a well-diversified portfolio.
Sutro Biopharma Fundamentals Growth
Sutro Stock prices reflect investors' perceptions of the future prospects and financial health of Sutro Biopharma, and Sutro Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sutro Stock performance.
| Return On Equity | -2.34 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (4.41) % | ||||
| Current Valuation | (227.06 M) | ||||
| Shares Outstanding | 83.78 M | ||||
| Price To Earning | 53.08 X | ||||
| Price To Book | 1.54 X | ||||
| Price To Sales | 1.07 X | ||||
| Revenue | 62.04 M | ||||
| Gross Profit | 49.54 M | ||||
| EBITDA | (238.45 M) | ||||
| Net Income | (227.46 M) | ||||
| Cash And Equivalents | 225.64 M | ||||
| Cash Per Share | 4.33 X | ||||
| Total Debt | 23.15 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 7.44 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (191.54 M) | ||||
| Earnings Per Share | (2.96) X | ||||
| Market Capitalization | 66.69 M | ||||
| Total Asset | 387.21 M | ||||
| Retained Earnings | (786.87 M) | ||||
| Working Capital | 211.42 M | ||||
About Sutro Biopharma Performance
By examining Sutro Biopharma's fundamental ratios, stakeholders can obtain critical insights into Sutro Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sutro Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (590.88) | (561.34) | |
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.93) | (0.89) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (5.10) | (4.84) |
Things to note about Sutro Biopharma performance evaluation
Checking the ongoing alerts about Sutro Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sutro Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sutro Biopharma generated a negative expected return over the last 90 days | |
| Sutro Biopharma has high historical volatility and very poor performance | |
| Sutro Biopharma has some characteristics of a very speculative penny stock | |
| Sutro Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 49.54 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sutro Biopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Sutro Biopharma lays off dozens of employees in strategic portfolio review - Yahoo News |
- Analyzing Sutro Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sutro Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Sutro Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sutro Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sutro Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sutro Biopharma's stock. These opinions can provide insight into Sutro Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.